SEARCH

SEARCH BY CITATION

References

  • Alp E, Koc RK, Durak AC, Yildiz O, Aygen B, Sumerkan B & Doganay M (2006) Doxycycline plus streptomycin versus ciprofloxacin plus rifampicin in spinal brucellosis [ISRCTN31053647]. BMC Infect Dis 6: 72.
  • Aman T, AR , Kulsoom R & Khokhar I (1995) Spectrophotometric determination of some antipsychotic phenothiazines Anal. Letter 28: 881892.
  • Ariza J, Gudiol F, Pallares R, Viladrich PF, Rufi G, Corredoira J & Miravitlles MR (1992) Treatment of human brucellosis with doxycycline plus rifampin or doxycycline plus streptomycin. A randomized, double-blind study. Ann Intern Med 117: 2530.
  • Belal F, El-Ashry SM, El Kerdawy MM & El Wasseef DR (2001) Spectrofluorimetric determination of streptomycin in dosage forms and in spiked plasma using 9,10-phenanthraquinone. J Pharmaceut Biomed 26: 435441.
  • Corbel MJ (1997) Brucellosis: an overview. Emerg Infect Dis 3: 213221.
  • De La Torre PM, Torrado G & Torrado S (2005) Poly (acrylic acid) chitosan interpolymer complexes for stomach controlled antibiotic delivery. J Biomed Mater Res B 72: 191197.
  • DelVecchio VG, Kapatral V, Redkar RJ et al. (2002) The genome sequence of the facultative intracellular pathogen Brucella melitensis. P Natl Acad Sci USA 99: 443448.
  • Deutel B, Greindl M, Thaurer M & Bernkop-Schnurch A (2008) Novel insulin thiomer nanoparticles: in vivo evaluation of an oral drug delivery system. Biomacromolecules 9: 278285.
  • Dizbay M, Kilic S, Hizel K & Arman D (2007) Tigecycline: its potential for treatment of brucellosis. Scand J Infect Dis 39: 432434.
  • Ersoy Y, Sonmez E, Tevfik MR & But AD (2005) Comparison of three different combination therapies in the treatment of human brucellosis. Trop Doct 35: 210212.
  • Falagas ME & Bliziotis IA (2006) Quinolones for treatment of human brucellosis: critical review of the evidence from microbiological and clinical studies. Antimicrob Agents Ch 50: 2233.
  • Forge A & Schacht J (2000) Aminoglycoside antibiotics. Audiol Neuro-Otol 5: 322.
  • Gaspar MM, Cruz A, Fraga AG, Castro AG, Cruz ME & Pedrosa J (2008) Developments on drug delivery systems for the treatment of mycobacterial infections. Curr Top Med Chem 8: 579591.
  • Gelperina S, Kisich K, Iseman MD & Heifets L (2005) The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am J Respir Crit Care 172: 14871490.
  • Grillo MJ, De Miguel MJ, Munoz PM, Marin CM, Ariza J & Blasco JM (2006) Efficacy of several antibiotic combinations against Brucella melitensis Rev 1 experimental infection in BALB/c mice. J Antimicrob Chemoth 58: 622626.
  • Jennings GJ, Hajjeh RA, Girgis FY et al. (2007) Brucellosis as a cause of acute febrile illness in Egypt. T Roy Soc Trop Med H 101: 707713.
  • Khalil RM, Murad FE, Yehia SA, El-Ridy MS & Salama HA (1996) Free versus liposome-entrapped streptomycin sulfate in treatment of infections caused by Salmonella enteritidis. Pharmazie 51: 182184.
  • Lecaroz C, Blanco-Prieto MJ, Burrell MA & Gamazo C (2006) Intracellular killing of Brucella melitensis in human macrophages with microsphere-encapsulated gentamicin. J Antimicrob Chemoth 58: 549556.
  • Lecaroz MC, Blanco-Prieto MJ, Campanero MA, Salman H & Gamazo C (2007) Poly(D,L-lactide-coglycolide) particles containing gentamicin: pharmacokinetics and pharmacodynamics in Brucella melitensis-infected mice. Antimicrob Agents Ch 51: 11851190.
  • Pappas G, Akritidis N & Tsianos E (2005) Effective treatments in the management of brucellosis. Expert Opin Pharmaco 6: 201209.
  • Pappas G, Papadimitriou P, Akritidis N, Christou L & Tsianos EV (2006a) The new global map of human brucellosis. Lancet Infect Dis 6: 9199.
  • Pappas G, Panagopoulou P, Christou L & Akritidis N (2006b) Brucella as a biological weapon. Cell Mol Life Sci 63: 22292236.
  • Reveneau N, Crane DD, Fischer E & Caldwell HD (2005) Bactericidal activity of first-choice antibiotics against gamma interferon-induced persistent infection of human epithelial cells by Chlamydia trachomatis. Antimicrob Agents Ch 49: 17871793.
  • Segura S, Gamazo C, Irache JM & Espuelas S (2007) Gamma interferon loaded onto albumin nanoparticles: in vitro and in vivo activities against Brucella abortus. Antimicrob Agents Ch 51: 13101314.
  • Seleem MN, Boyle SM & Sriranganathan N (2008) Brucella: a pathogen without classic virulence genes. Vet Microbiol 129: 114.
  • Shah LK & Amiji MM (2006) Intracellular delivery of saquinavir in biodegradable polymeric nanoparticles for HIV/AIDS. Pharm Res 23: 26382645.
  • Shasha B, Lang R & Rubinstein E (1994) Efficacy of combinations of doxycycline and rifampicin in the therapy of experimental mouse brucellosis. J Antimicrob Chemoth 33: 545551.
  • Sijian H, Chaikor EL, Taton D & Gnanou Y (2003) Synthesis of water-soluble star-block and dendrimer-like copolymers based on poly(ethylene oxide) and poly(acrylic acid). Macromolecules 36: 38743881.
  • Solera J, Rodriguez-Zapata M, Geijo P et al. (1995) Doxycycline–rifampin versus doxycycline–streptomycin in treatment of human brucellosis due to Brucella melitensis. The GECMEI Group. Grupo de Estudio de Castilla-la Mancha de Enfermedades Infecciosas. Antimicrob Agents Ch 39: 20612067.
  • Solera J, Martinez-Alfaro E & Espinosa A (1997) Recognition and optimum treatment of brucellosis. Drugs 53: 245256.
  • Trubetskoy VS, Wong SC, Subbotin V, Budker VG, Loomis A, Hagstrom JE & Wolff JA (2003) Recharging cationic DNA complexes with highly charged polyanions for in vitro and in vivo gene delivery. Gene Ther 10: 261271.
  • Vakulenko SB & Mobashery S (2003) Versatility of aminoglycosides and prospects for their future. Clin Microbiol Rev 16: 430450.
  • Verhoef HEJaJC (1998) Macromolecules as safe penetration enhancers for hydrophilic drugs – a fiction? Pharm Sci Technol To 1: 370376.
  • Weidner J (2001) Drug delivery. Drug Discov Today 6: 216217.